AbCellera Biologics Inc.
Price Action
Technical Summary
EMERGING TRENDAbCellera Biologics Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 7% provides fundamental context to the price action. Investors should exercise caution due to high volatility (78% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.60 | +0.59% | ABOVE |
| 50 SMA | $4.86 | +15.89% | ABOVE |
| 100 SMA | $4.12 | +36.51% | ABOVE |
| 150 SMA | $4.01 | +40.50% | ABOVE |
| 200 SMA | $4.27 | +31.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ABCL in an uptrend right now?
ABCL has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ABCL overbought or oversold?
ABCL's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is ABCL outperforming the market?
ABCL has a Relative Strength (RS) Rating of 89 out of 99. Yes, ABCL is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is ABCL in its 52-week range?
ABCL is trading at $5.63, which is 83% of its 52-week high ($6.79) and 71% above its 52-week low ($2.75).
How volatile is ABCL?
ABCL has a Beta of 2.70 and 52-week volatility of 78%. It's more volatile than the S&P 500 - expect bigger swings.